US Pharma MarketingDaiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion JPY ($19 billion) in 2030 revenues. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues.
The drugmaker published a new five-year business plan on Monday ...
Source: Endpoints News